A2 BIO
LIVE

Serial Number

97980568

Owner

A2 Biotherapeutics, Inc.

Attorney

Joi A. White

First Use Date

May 1, 2023

Filing Date

Feb 15, 2023

Add to watchlist:

No watchlists yet
View on USPTO

A2 BIO Trademark

Serial Number: 97980568 • Registration: 7961427

A2 BIO is a trademark filed by A2 Biotherapeutics, Inc. on February 15, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

A2 Biotherapeutics, Inc. (10 trademarks)

Agoura Hills, CA 91301

Entity Type: 03

Trademark Details

Filing Date

February 15, 2023

Registration Date

September 23, 2025

First Use Anywhere

May 1, 2023

First Use in Commerce

May 1, 2023

Published for Opposition

December 26, 2023

Goods & Services

Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer

Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy products, namely, genetically engineered tissues for transplant purposes

Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology research, development, testing and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 23, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 23, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 3, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 3, 2025 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 26, 2025 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Aug 25, 2025 SUPC
SOU EXTENSION 3 GRANTED
Aug 25, 2025 EX3G
DIVISIONAL PROCESSING COMPLETE
Aug 25, 2025 DPCC
SOU TEAS EXTENSION RECEIVED
Aug 12, 2025 EEXT
SOU EXTENSION 3 FILED
Aug 11, 2025 EXT3
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 11, 2025 AITU
USE AMENDMENT FILED
May 8, 2025 IUAF
DIVISIONAL REQUEST RECEIVED
May 8, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 8, 2025 ERTD
TEAS STATEMENT OF USE RECEIVED
May 8, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 20, 2025 EX2G
SOU EXTENSION 2 FILED
Feb 19, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 19, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 19, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 19, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 20, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 26, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 6, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 17, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 17, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 17, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 17, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 17, 2023 CNEA
ASSIGNED TO EXAMINER
Nov 14, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 6, 2023 NWOS
NEW APPLICATION ENTERED
Feb 18, 2023 NWAP